Search clinical trials for: methoxy polyethylene glycol-epoetin beta [Mircera]

Total 106 results

Hamad Medical Corporation

Completed

Comparison Among Erythropoietin Stimulating Agents

Anemia of End Stage Renal Disease

Qatar
Chugai Pharmaceutical

Completed

Correction Study of R744 in Renal Anemia Patients on Hemodialysis

Hemodialysis Patients

Japan
Hoffmann-La Roche

Completed

A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Anemia

Belgium, Italy, Spain, France, Sweden, Greece, United Kingdom, United States, Australia, Canada, Germany, Netherlands, Puerto Rico
Chugai Pharmaceutical

Completed

Clinical Study of R744 to Predialysis Patients

Anemia in Pre-Dialysis Patients

Japan
Hoffmann-La Roche

Terminated

A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients.

Anemia

United States
Hoffmann-La Roche

Completed

A Study of Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Predialysis Patients Not Treated With ESA.

Anemia

Turkey
Hoffmann-La Roche

Completed

MIRACLE Study: A Study of Once-Monthly Intravenous Mircera in Hemodialysis Participants With Chronic Renal Anemia

Anemia

Austria, Switzerland
Hoffmann-La Roche

Completed

A Study of Subcutaneous Mircera for the Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis

Anemia

France
Hoffmann-La Roche

Completed

A Study of Monthly Subcutaneous (SC) Mircera for Maintenance Treatment of Participants With Chronic Kidney Disease on Peritoneal Dialysis (MISTRAL)

Anemia

France
Hoffmann-La Roche

Completed

A Study of Once Monthly Subcutaneous Mircera in Dialysis Patients With Chronic Renal Anemia

Anemia

Morocco
Hoffmann-La Roche

Completed

A Study of Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia

Chronic Renal Anemia

Greece
Hoffmann-La Roche

Completed

A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia

Anemia

Belgium, France, Germany, Italy, Spain, United States, Australia, Sweden, Denmark, Taiwan, Greece, Netherlands, United Kingdom, South Africa, Switzerland, Austria, Thailand, Poland, Hungary, Russian Federation, Mexico, Czech Republic and more
Biocad

Completed

Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers

Reticulocyte Count
Hoffmann-La Roche

Completed

A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia

Anemia

Turkey
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Ro 50-3821 in Treating Anemia in Patients Receiving Antineoplastic Therapy for Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Anemia | Lung Cancer

United States
Chugai Pharmaceutical

Completed

Clinical Study of R744 to Hemodialysis Patients

Hemodialysis Patients

Japan
Hoffmann-La Roche

Completed

A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)

Chronic Renal Anemia

Belgium, Brazil, United Kingdom, Serbia, Spain, Germany, Korea, Republic of, Turkey, Lithuania, Italy, Czechia, Argentina, Australia, Croatia, France, Greece, Israel, Malaysia, Mexico, Panama, Philippines, Poland, Russian Federation, ... and more
Hoffmann-La Roche

Completed

A Study of Monthly Subcutaneous Continuous Erythropoietin Receptor Activator (CERA) in Predialysis Participants With Chronic Renal Anemia (ORION)

Anemia

Italy
Hoffmann-La Roche

Completed

A Study of Subcutaneous C.E.R.A. for the Maintenance of Hemoglobin Levels in Participants With Chronic Renal Anemia Not on Dialysis.

Anemia

Netherlands
Hoffmann-La Roche

Completed

An Observational Study of Methoxy Polyethylene Glycol-epoetin Beta in Participants With a Kidney Transplant

Anemia, Kidney Transplantation

Germany
Hoffmann-La Roche

Completed

A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

Anemia

Italy, Spain, France, Canada, Hungary, United States, Germany, Belgium, Poland, Australia, Israel, United Kingdom, Czech Republic
Hoffmann-La Roche

Terminated

A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.

Anemia

United States
Hoffmann-La Roche

Completed

An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Patients With Renal Anemia

Anemia

Germany
Hoffmann-La Roche

Completed

A Study of Subcutaneous C.E.R.A. for the Treatment of Anemia in Pre-Dialysis Patients.

Anemia

Russian Federation
University Hospital, Basel, Switzerland

Completed

Hemoglobin Kinetics in Response to Mircera® in Patients With Acute Myocardial Infarction (BEATSTEMIPi)

Acute Myocardial Infarction

Switzerland
Taipei Veterans General Hospital, Taiwan
Taipei City Hospital

Completed

Frequent Dosing of CERA Improves Nutrition and Inflammation in Hemodialysis Patients

Inflammation | Anemia | Malnutrition

Taiwan
Hoffmann-La Roche

Completed

A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Anemia

France, Italy, United States, Canada, Germany, Spain, Switzerland, Norway
EMD Serono Research & Development Institute, Inc.

Completed

A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD) (ONWARD)

Multiple Sclerosis

United States, Italy, Russian Federation, Spain
Fudan University

Recruiting

Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia

Obesity | Atypical Endometrial Hyperplasia | Fertility Issues

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Not yet recruiting

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

Metastatic Sarcoma | Resectable Sarcoma | Recurrent Sarcoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia | Ph-Like Acute Lymphoblastic Leukemia

United States
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Recurrent B Lymphoblastic Lymphoma | Refractory B Lymphoblastic Lymphoma

United States, Puerto Rico
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent T Acute Lymphoblastic Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

T Acute Lymphoblastic Leukemia | T Lymphoblastic Lymphoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)

Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia | Childhood B Acute Lymphoblastic Leukemia

United States, Canada, Australia
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

Acute Lymphoblastic Leukemia | Down Syndrome | Philadelphia Chromosome Positive | Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Childhood B Acute Lymphoblastic Leukemia | Adult B Lymphoblastic Lymphoma | Ann Arbor Stage I B Lymphoblastic Lymphoma | Ann Arbor Stage... and other conditions

United States, Canada, Puerto Rico, Australia, New Zealand, Switzerland, Ireland
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Childhood B Acute Lymphoblastic Leukemia

United States, Canada, Australia, New Zealand, Switzerland
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia | Childhood B Acute Lymphoblastic Leukemia

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia | Childhood B Acute Lymphoblastic Leukemia

United States, Canada, Australia, New Zealand, Switzerland
National Cancer Institute (NCI)

Withdrawn

Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)

T Acute Lymphoblastic Leukemia | T Lymphoblastic Lymphoma
National Cancer Institute (NCI)

Suspended

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Down Syndrome | Recurrent B Acute Lymphoblastic Leukemia

United States, Canada, Puerto Rico, Australia
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

Adult T Acute Lymphoblastic Leukemia | Childhood T Acute Lymphoblastic Leukemia | Ann Arbor Stage II Adult Lymphoblastic Lymphoma | Ann Arbor Stage II Childhood Lymphoblastic Lymphoma | Ann Arbor Stage III Adult Lymphoblastic Lymphoma | Ann Arbor Stage III Childhood Lymphoblastic Lymphoma | Ann... and other conditions

United States, Canada, Australia, New Zealand
National Cancer Institute (NCI)

Active, not recruiting

Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

B Acute Lymphoblastic Leukemia | Acute Leukemia of Ambiguous Lineage | Mixed Phenotype Acute Leukemia

United States, Canada, Puerto Rico, Australia
National Cancer Institute (NCI)

Not yet recruiting

A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)

B Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

T Acute Lymphoblastic Leukemia | T Lymphoblastic Lymphoma

United States, Canada, Australia, New Zealand, Switzerland
National Cancer Institute (NCI)
Canadian Cancer Trials Group

Active, not recruiting

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

United States, Canada, Israel, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

B Acute Lymphoblastic Leukemia | Central Nervous System Leukemia | Testicular Leukemia | B Acute Lymphoblastic Leukemia, BCR-ABL1-Like

United States, Canada, Puerto Rico, Australia, New Zealand, Switzerland, Ireland
National Cancer Institute (NCI)

Active, not recruiting

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia

United States, Canada, Puerto Rico, Australia, New Zealand
M.D. Anderson Cancer Center
Jazz Pharmaceuticals

Terminated

Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Lymphoma | Leukemia | Lymphoblastic Lymphoma | Precursor-B Acute Lymphoblastic Leukemia

United States
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

B Acute Lymphoblastic Leukemia | Central Nervous System Leukemia | Testicular Leukemia | B Lymphoblastic Lymphoma | Mixed Phenotype Acute Leukemia

United States, Canada, Australia, Puerto Rico, New Zealand

Search clinical trials for: methoxy polyethylene glycol-epoetin beta [Mircera]

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations